Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBG453 (sabatolimab) + azacitidine + venetoclax in unfit AML adults
2019-000439-14Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sabatolimab in acute myeloid leukemia (AML), sponsored by Novartis. Primary endpoint: Incidence of dose limiting toxicities. Started Dec 2020; status: completed.
02
Drugs
sabatolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-000439-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000439-14.